+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating new treatment options for people with locally advanced, unresected non-small cell lung cancer NSCLC that has a KRAS G12C gene mutation. This trial aims to learn if combining calderasib MK-1084 with durvalumab, an immunotherapy, after chemotherapy and radiation can help patients live longer without their cancer growing or spreading. Participants will be randomly assigned to receive either calderasib along with durvalumab or a placebo with durvalumab. Calderasib is taken as an oral tablet, while durvalumab is given by intravenous infusion. The study is blinded so neither participants nor researchers know who receives the active drug or placebo during treatment. During the study, participants will be monitored regularly to assess cancer progression, survival, quality of life, and side effects. This includes tumor testing, blood work, and questionnaires over up to approximately 6 years for progression-free survival and up to 9 years for overall survival and other health measures. The study is sponsored by Merck Sharp & Dohme LLC and follows participants from screening through long-term follow-up.

Age: 18Years +All GendersPhase 3
107 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared with pembrolizumab plus pemetrexed and carboplatin or cisplatin for adults with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have not received prior treatment. This phase 3 randomized study aims to find the best first-line therapy option for this specific lung cancer type. Participants are randomly assigned to one of two groups one group receives divarasib orally once daily and pembrolizumab through intravenous infusion every three weeks, while the other group receives pembrolizumab, pemetrexed, and carboplatin or cisplatin all by intravenous infusion every three weeks. The study treatments are given as first-line therapy, and participants are monitored for up to approximately five years. During the study, participants undergo regular assessments including scans to measure tumor response, evaluations of lung cancer symptoms like cough and breathlessness, quality of life questionnaires, and monitoring for side effects. Researchers track progression-free survival and overall survival for up to about five years. Safety and symptom severity are closely followed throughout the study, providing comprehensive data on treatment impact and participant well-being.

Age: 18Years +All GendersPhase 3
288 locations
E

Actively Recruiting

Researchers are evaluating the safety, pharmacokinetics, and activity of the drug divarasib alone or combined with other anti-cancer treatments in adults with previously untreated advanced or metastatic non-small cell lung cancer NSCLC that has a KRAS G12C mutation. This phase IbII open-label study involves participants who have not received prior systemic treatment for advanced or metastatic NSCLC and aims to better understand how divarasib works and its side effects. Participants will be assigned to different groups receiving divarasib orally once daily at varying dose levels combined with pembrolizumab given as an intravenous infusion every three weeks. Some groups will also receive platinum-based chemotherapy carboplatin or cisplatin and pemetrexed. The study includes dose finding and dose expansion stages, with some participants randomized to different combination dose levels of divarasib and pembrolizumab. During the study, participants will be monitored for adverse events from baseline until 60 days after the last dose or until starting another anti-cancer therapy, up to about five years. Researchers will assess response rates, duration of response, progression-free survival, symptom side effects through patient questionnaires, and drug levels in plasma or cerebrospinal fluid. Safety and activity will be observed through regular clinical visits, imaging, and laboratory tests throughout the study period.

Age: 18Years +All GendersPhase 1Phase 2
71 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.

Age: 18Years +All GendersPhase 3
317 locations
P

Actively Recruiting

Researchers are evaluating whether intismeran autogene, given with pembrolizumab and chemotherapy, can improve outcomes for people with metastatic treatment-naive squamous non-small cell lung cancer NSCLC. This study compares the combination of intismeran autogene with pembrolizumab and chemotherapy against a placebo with pembrolizumab and chemotherapy to see if it helps patients live longer without the cancer growing or spreading. The trial is a randomized, double-blind, placebo-controlled Phase 2 study sponsored by Merck Sharp & Dohme LLC. Participants receive treatments in two phases induction and maintenance. During the induction phase, pembrolizumab is given by intravenous infusion every six weeks combined with a platinum-based chemotherapy regimen and either paclitaxel or nab-paclitaxel. Intismeran autogene or placebo injections are administered intramuscularly on specific days during the induction phase. In the maintenance phase, pembrolizumab continues every six weeks, and intismeran autogene or placebo injections are given every three weeks for up to seven doses. Participants will be closely monitored throughout the study with regular assessments including scans, laboratory tests, and evaluations of their cancers response and overall health. The main outcomes measured are progression-free survival and overall survival over approximately 32 to 42 months. Secondary outcomes include response rates, duration of response, and the occurrence of side effects. The study aims to collect comprehensive data to understand the effects and safety of the study treatment combination compared to placebo.

Age: 18Years +All GendersPhase 2
55 locations
P

Actively Recruiting

Researchers are investigating the efficacy of divarasib compared with the investigators choice of immunotherapy pembrolizumab or nivolumab or observation in adults with resected Stage II-IIIB non-small cell lung cancer NSCLC that tests positive for the KRAS G12C mutation. This study focuses on participants who have not achieved a complete pathological response following neoadjuvant chemoimmunotherapy, regardless of tumor PD-L1 status. The trial aims to assess disease-free survival and overall survival in this patient group. Participants will be randomly assigned to one of two groups. One group will receive divarasib orally once daily for up to 52 cycles, each cycle lasting 21 days. The other group will receive either pembrolizumab or nivolumab immunotherapy, administered according to prior treatment type, or will be observed without study treatment. Pembrolizumab is given as an intravenous infusion every three weeks or a subcutaneous injection every three weeks for up to 13 cycles. Nivolumab is given as an intravenous infusion or subcutaneous injection every four weeks for up to 13 cycles. Observation participants will not receive any study treatment. Throughout the study, participants will be monitored for disease recurrence or death for up to approximately five years to assess disease-free survival. Additional outcomes include overall survival for up to eight years, adverse events tracking up to 60 days after treatment ends, and disease-free survival rates at two and three years. Participants will undergo regular evaluations to monitor their health status and study outcomes. The total duration of participation may extend up to eight years from randomization.

Age: 18Years +All GendersPhase 3
46 locations
R

Actively Recruiting

Researchers are evaluating whether adding zilovertamab vedotin to the standard treatment can help people with previously untreated diffuse large B-cell lymphoma DLBCL live longer without their cancer growing or spreading. This phase 3 randomized study compares the combination of zilovertamab vedotin with rituximab plus cyclophosphamide, doxorubicin, and prednisone R-CHP against the standard treatment of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP. Participants receive treatments in 21-day cycles for up to six cycles approximately four months. One group receives zilovertamab vedotin with rituximab or its biosimilar, cyclophosphamide, doxorubicin, and prednisone or similar steroids, while the other group receives rituximab or its biosimilar, cyclophosphamide, doxorubicin, vincristine, and prednisone or similar steroids. Both groups may receive up to two additional cycles of rituximab or its biosimilar as decided by the investigator. During the study, participants will have regular assessments including imaging scans and heart function tests to monitor their health and response to treatment. Researchers will measure how long participants live without disease progression, overall survival, response rates, and quality of life up to several years. Safety is monitored by tracking adverse events and treatment discontinuations. The study lasts several years, with primary outcome assessments up to about 50 months and overall survival monitored up to approximately 74 months.

Age: 18Years +All GendersPhase 3
285 locations
E

Actively Recruiting

Researchers are evaluating zongertinib, an oral HER2-targeted drug, to see if it can improve outcomes compared to standard adjuvant treatments in adults with completely removed Stage II to IIIB non-small cell lung cancer NSCLC that has activating HER2 tyrosine kinase domain mutations. This Phase 3, global, randomized, open-label study includes participants who have had surgery with curative intent and received perioperative systemic therapy such as neoadjuvant platinum-based chemotherapy with or without immunotherapy, or adjuvant platinum-based chemotherapy. Participants are randomly assigned to one of two groups one group takes zongertinib daily by mouth for up to three years, while the other group follows standard care, which may include approved adjuvant immunotherapy or observation based on local guidelines and patient condition. This comparison aims to determine if zongertinib can extend disease-free survival. Safety, overall survival, tolerability, and patient-reported outcomes are also monitored during the study. During the study, participants undergo regular evaluations including disease assessments by investigators for up to 8 years and 5 months to measure disease-free survival and overall survival. Safety is tracked by recording adverse events, especially those of grade 3 or higher, from treatment start through up to three years or tumor recurrence. Participants provide tumor tissue samples for HER2 status confirmation, and their overall health and organ functions are monitored. The entire study lasts several years, including follow-up to assess long-term outcomes.

Age: 18Years +All GendersPhase 3
203 locations
S

Actively Recruiting

Researchers are evaluating a new treatment combination for adults with advanced small cell lung cancer SCLC. The study compares a medicine called obrixtamig combined with standard treatment atezolizumab, carboplatin, and etoposide against the standard treatment alone. Obrixtamig is an antibody-like molecule designed to help the immune system fight cancer. The study also tests a new medical device to measure levels of a tumor marker called DLL3. Participants are randomly assigned to one of two groups. One group receives obrixtamig plus the standard treatment, while the other group receives only the standard treatment. All drugs are given through infusions into a vein. Participants in the obrixtamig group stay overnight at the study site after their first two obrixtamig treatments. The study lasts for up to three years, during which participants visit the study site regularly. Throughout the study, doctors monitor tumor size to compare results between groups. They also check participants overall health and note any side effects. Researchers measure outcomes such as overall survival, progression-free survival, symptom changes, treatment responses, and any treatment-related side effects. Participants are closely observed for up to 36 months to evaluate these effects and safety.

Age: 18Years +All GendersPhase 3
243 locations
P

Actively Recruiting

Researchers are evaluating the combination of brenetafusp IMC-F106C plus nivolumab compared to standard nivolumab regimens in people with previously untreated advanced melanoma who are HLA-A*0201-positive. This phase 3, randomized, controlled study aims to understand how these treatments perform in this specific group. The study focuses on improving progression-free survival and overall outcomes for participants with advanced melanoma. Participants are assigned to one of three groups one group receives a low dose of brenetafusp once weekly for 13 weeks, then every two weeks until Week 51, and every four weeks thereafter, along with nivolumab every four weeks another group receives a high dose of brenetafusp on the same schedule plus nivolumab the third group receives nivolumab alone or nivolumab combined with relatlimab every four weeks. The study includes a dose recommendation phase with changes made in November 2025 based on safety and efficacy data. During the study, participants undergo assessments including tumor measurements per RECIST 1.1, BRAF V600 mutation status evaluation, and performance status scoring. Researchers will monitor progression-free survival up to approximately 45 months, overall survival up to 57 months, and record adverse events, immune responses, and quality of life. The study involves regular dosing and long-term follow-up to evaluate treatment effects and safety.

Age: 18Years +All GendersPhase 3
211 locations

1-10 of 12

1